ESR1 and inflammatory breast carcinoma: Stratified by subtype, the CN gain was identified in 6 out of 8 ER+ IBC patients (chr7: 58,019,983–58,025,423) vs. 199 out of 338 ER+ non-IBC patients (FDR p-value = 3.12 × 10−10) and 3 out of 3 TN-IBC patients (chr7: 57,950,944–58,025,423) vs. 0 out of 50 TN non-IBC patients (FDR p-value = 4.27 × 10−5).